Key result
Following an acute coronary event, 15.1% of patients on ASA monotherapy and 37.5% on dual antiplatelet therapy discontinued treatment within 1 year, with bleeding as the strongest predictor.
Why the study?
What are the trends in prescription and discontinuation of antiplatelet therapy following an acute coronary event in UK primary care?
Population
27,351 patients aged 50 to 84 years who experienced an acute coronary event in a UK primary care setting…
Design
Cohort
Follow-up
up to 2 years
Authors
Loading...
High discontinuation rates post-event, especially DAPT driven by bleeding, warrant monitoring; observational data leaves open strategies to improve persistence.
Observational (n=27,351)
What are the trends in prescription and discontinuation of antiplatelet therapy following an acute coronary event in UK primary care?
Despite high initial prescription rates of antiplatelet therapy post-acute coronary event, a substantial proportion of patients discontinue treatment within 1 year, often driven by bleeding events.
Sáez et al. (2014) conducted an observational in Acute coronary event (n=27,351). Antiplatelet therapy was evaluated on Exposure to and discontinuation of antiplatelet therapy. Following an acute coronary event, 15.1% of patients on ASA monotherapy and 37.5% on dual antiplatelet therapy discontinued treatment within 1 year, with bleeding as the strongest predictor.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: